methyl 1-(2-thienyl)cycloheptanecarboxylate | 1026791-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: methyl 1-(2-thienyl)cycloheptanecarboxylate
• 英文别名: methyl 1-thiophen-2-ylcycloheptane-1-carboxylate
• CAS: 1026791-34-3
• 化学式: C₁₃H₁₈O₂S
• 分子量: 238.351
• InChiKey: GUTAHYYMQSYKBB-UHFFFAOYSA-N

物化性质

• 沸点：
  325.3±25.0 °C(Predicted)
• 密度：
  1.114±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-甲基-4-哌啶醇 、 methyl 1-(2-thienyl)cycloheptanecarboxylate 在 sodium hydride 作用下， 以 甲苯 为溶剂， 反应 5.0h， 生成 1-methylpiperidin-4-yl 1-(2-thienyl)cycloheptanecarboxylate
  参考文献：
  名称：

  WO2008/59239

  摘要：

  公开号：
• 作为产物：
  描述：

  环庚酮 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 24.5h， 生成 methyl 1-(2-thienyl)cycloheptanecarboxylate
  参考文献：
  名称：

  The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD

  摘要：

  A novel series of muscarinic receptor antagonists was developed, with the aim of identifying a compound with high M-3 receptor potency and a reduced risk of dose-limiting side effects with potential for the treatment of COPD.Initial compound modifications led to a novel cycloheptyl series, which was improved by focusing on a quinuclidine sub-series. A wide range of N-substituents was evaluated to determine the optimal substituent providing a high M-3 receptor potency, high intrinsic clearance and high human plasma protein binding. Compounds achieving in vitro study criteria were selected for in vivo evaluation. Pharmacokinetic half-lives, inhibition of bronchoconstriction and duration of action, as well as systemic side effects, induced by the compounds were assessed in guinea-pig models.Compounds with a long duration of action and good therapeutic index were identified and AZD8683 was selected for progression to the clinic. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.092

文献信息

• Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
  申请人：AstraZeneca AB

  公开号：EP2256117A1

  公开（公告）日：2010-12-01

  The invention provides compounds of formula (I) wherein R4 is a group of formula (II) or (IIIa) or (IIIb) and R1, R2, R3, R5, a, b and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation

  本发明提供了式 (I) 的化合物（其中 R4 是式 (II) 或 (IIIa) 或 (IIIb) 的基团，R1、R2、R3、R5、a、b 和 X 如说明书中所定义）、其制备方法、含有它们的药物组合物、药物组合物的制备方法、它们在治疗中的用途以及用于制备它们的中间体。
• WO2008/59245
  申请人：——

  公开号：——

  公开（公告）日：——
• QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：AstraZeneca AB

  公开号：EP2094694A1

  公开（公告）日：2009-09-02
• US8207193B2
  申请人：——

  公开号：US8207193B2

  公开（公告）日：2012-06-26
• [EN] NOVEL COMPOUNDS 514<br/>[FR] NOUVEAUX COMPOSÉS 514
  申请人：ASTRAZENECA AB

  公开号：WO2008059239A1

  公开（公告）日：2008-05-22

  [EN] The invention provides compounds of formula (I), wherein R¹, R², R³, R⁴, R⁵, g, h and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.
  [FR] L'invention concerne des composés représentés par la formule (I), dans laquelle R¹, R², R³, R⁴, R^5, g, h et X correspondent à leur définition dans le descriptif, un procédé servant à les préparer, des compositions pharmaceutiques les contenant, un procédé servant à préparer ces compositions pharmaceutiques, leur utilisation thérapeutique, ainsi que des intermédiaires à leur préparation.